RU2583900C2 - Соединения 2-арилбензофуран-7-формамида, способ их получения и применение - Google Patents

Соединения 2-арилбензофуран-7-формамида, способ их получения и применение Download PDF

Info

Publication number
RU2583900C2
RU2583900C2 RU2014132159/04A RU2014132159A RU2583900C2 RU 2583900 C2 RU2583900 C2 RU 2583900C2 RU 2014132159/04 A RU2014132159/04 A RU 2014132159/04A RU 2014132159 A RU2014132159 A RU 2014132159A RU 2583900 C2 RU2583900 C2 RU 2583900C2
Authority
RU
Russia
Prior art keywords
compound
methyl
mmol
preparation
fluoro
Prior art date
Application number
RU2014132159/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2014132159A (ru
Inventor
Чуньхао ЯН
Цзехун МЯО
Дзянь ДИН
Мэн ВАН
Цзиньсюэ ХЭ
Цунь ТАНЬ
И Чэнь
Original Assignee
Шанхай Инститьют Оф Матириа Медика, Чайниз Экэдеми Оф Сайэнсиз
Цызен Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шанхай Инститьют Оф Матириа Медика, Чайниз Экэдеми Оф Сайэнсиз, Цызен Фармасьютикал Ко., Лтд. filed Critical Шанхай Инститьют Оф Матириа Медика, Чайниз Экэдеми Оф Сайэнсиз
Publication of RU2014132159A publication Critical patent/RU2014132159A/ru
Application granted granted Critical
Publication of RU2583900C2 publication Critical patent/RU2583900C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
RU2014132159/04A 2012-02-09 2013-01-14 Соединения 2-арилбензофуран-7-формамида, способ их получения и применение RU2583900C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210028895.0A CN103242273B (zh) 2012-02-09 2012-02-09 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
CN201210028895.0 2012-02-09
PCT/CN2013/070410 WO2013117120A1 (zh) 2012-02-09 2013-01-14 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途

Publications (2)

Publication Number Publication Date
RU2014132159A RU2014132159A (ru) 2016-03-27
RU2583900C2 true RU2583900C2 (ru) 2016-05-10

Family

ID=48922178

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014132159/04A RU2583900C2 (ru) 2012-02-09 2013-01-14 Соединения 2-арилбензофуран-7-формамида, способ их получения и применение

Country Status (8)

Country Link
US (1) US9533965B2 (cg-RX-API-DMAC7.html)
EP (1) EP2813495B1 (cg-RX-API-DMAC7.html)
JP (1) JP5926821B2 (cg-RX-API-DMAC7.html)
CN (1) CN103242273B (cg-RX-API-DMAC7.html)
BR (1) BR112014019402B1 (cg-RX-API-DMAC7.html)
CA (1) CA2863988C (cg-RX-API-DMAC7.html)
RU (1) RU2583900C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013117120A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2783418C1 (ru) * 2018-05-31 2022-11-14 Шангхаи Институте Оф Материа Медика, Чайнесе Академи Оф Сайнсес Способ получения полиморфа гидрохлорида 2-[4-(метиламинометил)фенил]-5-фтор-бензофуран-7-карбоксамида

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用
MX2015006780A (es) 2012-12-31 2015-08-06 Cadila Healthcare Ltd Derivados de ftalazin-1-(2h)-ona sustituida.
CN105272936B (zh) * 2014-05-27 2019-05-17 中国科学院上海药物研究所 一类氮芳基苯并噻唑类parp抑制剂及其制备方法和用途
CN109134409B (zh) 2017-06-14 2023-09-29 中国科学院上海药物研究所 盐酸美呋哌瑞多晶型物及其制备方法与应用
CN111320596B (zh) * 2018-12-14 2024-07-05 甫康(上海)健康科技有限责任公司 盐酸美呋哌瑞多晶型物及其制备方法
JP7805005B2 (ja) * 2019-12-31 2026-01-23 フーカン(シャンハイ) ヘルス テクノロジー カンパニー、 リミテッド 腫瘍治療の医薬組み合わせとその使用
US20240016775A1 (en) 2020-02-24 2024-01-18 Fukang (Shanghai) Health Technology Co., Ltd Anti-coronavirus application of poly adp ribose polymerase inhibitor
EP4682143A1 (en) 2023-03-10 2026-01-21 Convalife Pharmaceuticals Co., Ltd. Pharmaceutical composition containing egfr inhibitor, and preparation method therefor and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007059230A2 (en) * 2005-11-15 2007-05-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2007131016A2 (en) * 2006-05-02 2007-11-15 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
RU2006117789A (ru) * 2003-10-24 2007-11-27 Уайт (Us) Производные дигидробензофуранилалканамина в качестве агонистов 5нт2с

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87451A0 (en) 1987-09-04 1989-01-31 Tanabe Seiyaku Co Benzofuran derivatives,their preparation and pharmaceutical compositions containing them
JP2002515488A (ja) * 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びparp活性の抑制方法
TR200101239T2 (tr) * 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
JP2002529537A (ja) * 1998-11-17 2002-09-10 ビーエーエスエフ アクチェンゲゼルシャフト 2−フェニルベンズイミダゾールおよび2−フェニルインドール、その製造方法ならびに使用
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
DE10351315A1 (de) 2003-10-31 2005-06-16 Aventis Pharma Deutschland Gmbh 2-Phenyl-benzofuran-Derivate, Verfahren zur ihrer Herstellung und ihre Verwendung
CA2580833C (en) * 2004-09-22 2010-12-21 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
MX347085B (es) * 2006-12-28 2017-04-06 Abbott Laboratories * Inhibidores de la poli (adp-ribosa) polimerasa.
JP2010518146A (ja) 2007-02-16 2010-05-27 グラクソ グループ リミテッド ベンゾフラン化合物
US20090010884A1 (en) * 2007-07-06 2009-01-08 Wyeth Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
CN101998959B (zh) * 2008-02-06 2013-08-28 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
GB0806656D0 (en) 2008-04-11 2008-05-14 Karobio Ab Novel estrogen receptor ligands
US8569336B2 (en) * 2008-11-10 2013-10-29 Ling Tong Compounds for the treatment of inflammatory disorders
US8476309B2 (en) 2009-08-20 2013-07-02 The University Of Tennessee Research Foundation Benzofuran cannabinoid compounds and related methods of use
GB0919380D0 (en) 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006117789A (ru) * 2003-10-24 2007-11-27 Уайт (Us) Производные дигидробензофуранилалканамина в качестве агонистов 5нт2с
WO2007059230A2 (en) * 2005-11-15 2007-05-24 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
WO2007131016A2 (en) * 2006-05-02 2007-11-15 Abbott Laboratories Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2783418C9 (ru) * 2017-06-14 2023-02-20 Шангхаи Институте Оф Материа Медика, Чайнесе Академи Оф Сайнсес Способ получения полиморфа гидрохлорида 2-[4-(метиламинометил)фенил]-5-фтор-бензофуран-7-карбоксамида
RU2783418C1 (ru) * 2018-05-31 2022-11-14 Шангхаи Институте Оф Материа Медика, Чайнесе Академи Оф Сайнсес Способ получения полиморфа гидрохлорида 2-[4-(метиламинометил)фенил]-5-фтор-бензофуран-7-карбоксамида

Also Published As

Publication number Publication date
RU2014132159A (ru) 2016-03-27
CN103242273B (zh) 2015-06-03
BR112014019402A8 (pt) 2017-07-11
US20150018542A1 (en) 2015-01-15
BR112014019402A2 (cg-RX-API-DMAC7.html) 2017-06-20
WO2013117120A1 (zh) 2013-08-15
BR112014019402B1 (pt) 2020-12-15
EP2813495A4 (en) 2015-06-17
JP5926821B2 (ja) 2016-05-25
JP2015511942A (ja) 2015-04-23
EP2813495B1 (en) 2016-09-28
CA2863988A1 (en) 2013-08-15
CA2863988C (en) 2016-03-22
US9533965B2 (en) 2017-01-03
CN103242273A (zh) 2013-08-14
EP2813495A1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
EP2813495B1 (en) 2-arylbenzofuran-7-formamide compounds, preparation method and use thereof
CN113603647B (zh) Parp抑制剂-烷基化双功能分子及其制备方法和应用
WO2021249558A1 (zh) 作为rsk抑制剂的蝶啶酮衍生物及其应用
JP6533875B2 (ja) Pde1阻害剤
CN115768761B (zh) 新颖苯并咪唑衍生物
CN112979571B (zh) 一类akr1c3选择性抑制剂及其制备方法与用途
HK1244278B (zh) 喹唑啉衍生物的盐及其制备方法
CN102070618B (zh) 一种化合物及其晶体
CN103748074B (zh) 芳氧基喹啉类衍生物及其治疗用途
CN108069954A (zh) 含no供体的喹唑啉酮化合物
CN102164905A (zh) 作为体内缺氧模拟剂的化合物,组合物,及其应用
CN110099685A (zh) 溴结构域抑制剂
EP3684354B1 (en) Xpa inhibitor compounds and their use
CN109336829B (zh) 含1,2,3-三氮唑结构的芳基甲酰胺类化合物及其用途
EP2800566B1 (en) Therapeutic use of imidazopyridine derivatives
CN104945411A (zh) 噻吩并[3,2-c]吡啶类化合物、其制备方法及应用
CN102775381A (zh) 取代的酰肼类化合物及其制备方法、药物组合物和用途
CN102746241B (zh) 2,3,5-三取代苯甲酰胺类化合物及其制备方法和用途
CN111454229A (zh) 二氢萘并异噁唑类衍生物及其在抗肿瘤药物中的应用
CN111559982B (zh) 2-(2-取代-4-羟基嘧啶-5-甲酰胺基)乙酸类化合物及其制备方法与用途
CN111018686B (zh) 6-苄亚基-2-芳基乙炔基环己烯酮衍生物及其制备方法和医药用途
CN114621206A (zh) 一种5-取代的嘧啶二胺类衍生物及其制备方法与应用
CN120114459B (zh) 苯并呋喃嘧啶酮或苯并噻吩嘧啶酮类化合物的应用
EP3632912B1 (en) Pyridoquinazoline derivatives useful as protein kinase inhibitors
CN108586432B (zh) 一种3-(吲哚-5-基)-吲唑衍生物及其应用

Legal Events

Date Code Title Description
PC41 Official registration of the transfer of exclusive right

Effective date: 20170629